Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

EHR intervention targets acute kidney injuries after PCI

Contrast-associated acute kidney injury is a significant problem in cardiology, especially among patients undergoing percutaneous coronary intervention. Can EHR-generated alerts make an impact?

January 18, 2023
 The Neovasc Reducer System is designed to treat the symptoms of refractory angina by altering a patient's blood flow.

Shockwave Medical to acquire medical device company for $100M

Shockwave Medical's decision to acquire Neovasc is based largely on the potential of the Neovasc Reducer System, a solution designed to treat the symptoms of refractory angina by altering a patient's blood flow.

January 17, 2023
Abbott has gained U.S. Food and Drug Administration (FDA) approval for its Navitor transcatheter aortic valve replacement (TAVR) system, the company’s new Navitor self-expanding valve for high-risk patients with severe symptomatic aortic stenosis.

Abbott receives FDA approval for new self-expanding TAVR system

The device, which gained CE mark approval in Europe in May 2021, features a new-look fabric cuff designed to keep the risk of paravalvular leak (PVL) at a minimum.

January 17, 2023
Fysicon’s QMAPP Hemodynamic Monitoring Device

Canon Medical Systems announces new partnership focused on enterprise imaging and hemodynamics

The partnership is with ScImage, a California-based healthcare technology company known for its extensive EI background.

January 16, 2023
hospital ward

How cardiologists can improve in-hospital outcomes after PCI

Researchers evaluated if two recently developed risk scores can anticipate adverse in-hospital outcomes after PCI, sharing their findings in the American Journal of Cardiology.

January 16, 2023
PCI. Long-term P2Y12 inhibitor monotherapy after an initial three months of dual antiplatelet therapy (DAPT) is associated with three-year percutaneous coronary intervention (PCI) outcomes similar to prolonged DAPT, according to new research published in JAMA Cardiology.[1] The study’s authors noted that this strategy was also associated with a lower risk of bleeding events than prolonged DAPT. Photo courtesy of Jose Arellano.

A new antiplatelet strategy for treating diabetic PCI patients

Clopidogrel monotherapy after just one month of DAPT was associated with promising outcomes, including a reduction in bleeding events.

January 13, 2023

How intravascular lithotripsy can improve TMVR outcomes

The IVL technology developed by Shockwave Medical helped clinicians treat a TMVR patient who had previously undergone TAVR. Could this be a common use of IVL in the future?

January 12, 2023

Medtronic enrolls first patient for head-to-head EVAR study

The randomized trial, expected to enroll at least 550 patients, will follow patients for a total of five years.

January 11, 2023

Press Releases

Trimed Popup
Trimed Popup